Straumann vs Nobel Biocare

Quick answer

These are the two premium brands most patients have heard of, and both sit inside larger corporations — Straumann within the Straumann Group, Nobel Biocare within Envista. Neither is universally better; they run different, incompatible connection systems, and the more useful record after treatment is the system and connection, not the brand.

Side by side

Rows appear only where at least one side has data. Where a value is not verified we say so rather than leaving it blank.

Attribute	Straumann	Nobel Biocare
Parent company	Straumann Holding AG, Basel, SwitzerlandVerified spec[1]	Envista Holdings Corporation, Brea, CaliforniaVerified spec[2]
Country of origin	SwitzerlandVerified spec[1]	SwitzerlandVerified spec[5]
Founded	Institut Straumann was founded in 1954 in Waldenburg, Switzerland; the business was refocused exclusively on dental implantology in 1990Verified spec[1]	Nobelpharma was founded in Gothenburg, Sweden in 1981 and renamed Nobel Biocare in 1996; the underlying work is Per-Ingvar Brånemark’s, who placed the first titanium dental implant in 1965Verified spec[5]
Ownership	Not publicly verified	Owned by Envista Holdings. Danaher Corporation completed its acquisition of Nobel Biocare Holding AG on 11 December 2014, taking about 97% of the shares and moving to delist the company from the SIX Swiss Exchange; Envista was formed inside Danaher in 2018 and separated in 2019, taking Nobel Biocare with itVerified spec[6][2][4]Nobel Biocare’s own timeline dates the Danaher acquisition to 2015; Danaher’s completion release is dated 11 December 2014, with the squeeze-out and delisting following in the first quarter of 2015. The two dates describe different stages of the same transaction.
Manufacturer	Straumann Group (Straumann Holding AG)Verified spec[1]	Envista Holdings CorporationVerified spec[2][3][4]
Current status	Current — the group’s flagship implant brandVerified spec[1]	Not publicly verified

Parent company

Straumann

Straumann Holding AG, Basel, SwitzerlandVerified spec[1]

Nobel Biocare

Envista Holdings Corporation, Brea, CaliforniaVerified spec[2]

Country of origin

Straumann

SwitzerlandVerified spec[1]

Nobel Biocare

SwitzerlandVerified spec[5]

Founded

Straumann

Institut Straumann was founded in 1954 in Waldenburg, Switzerland; the business was refocused exclusively on dental implantology in 1990Verified spec[1]

Nobel Biocare

Nobelpharma was founded in Gothenburg, Sweden in 1981 and renamed Nobel Biocare in 1996; the underlying work is Per-Ingvar Brånemark’s, who placed the first titanium dental implant in 1965Verified spec[5]

Ownership

Straumann

Not publicly verified

Nobel Biocare

Owned by Envista Holdings. Danaher Corporation completed its acquisition of Nobel Biocare Holding AG on 11 December 2014, taking about 97% of the shares and moving to delist the company from the SIX Swiss Exchange; Envista was formed inside Danaher in 2018 and separated in 2019, taking Nobel Biocare with itVerified spec[6][2][4]Nobel Biocare’s own timeline dates the Danaher acquisition to 2015; Danaher’s completion release is dated 11 December 2014, with the squeeze-out and delisting following in the first quarter of 2015. The two dates describe different stages of the same transaction.

Manufacturer

Straumann

Straumann Group (Straumann Holding AG)Verified spec[1]

Nobel Biocare

Envista Holdings CorporationVerified spec[2][3][4]

Current status

Straumann

Current — the group’s flagship implant brandVerified spec[1]

Nobel Biocare

Not publicly verified

The biggest differences

Straumann is the premium implant brand of the Straumann Group, which also owns Neodent, Anthogyr and Medentika. Nobel Biocare descends from Per-Ingvar Brånemark's original titanium implant work and is now owned by Envista, which also runs the value brands Implant Direct and Alpha-Bio Tec. So both brands are the premium face of a group that sells across the price range — a quote for 'a Straumann Group implant' or 'a Nobel implant' may not name the brand you assume.

Prosthetic ecosystem

This is where the brands genuinely diverge. Straumann runs several connection systems — CrossFit on its bone-level implants, TorcFit on BLX and TLX, synOcta on its classic tissue-level implants. Nobel Biocare runs its internal conical connection across NobelActive, NobelParallel and NobelReplace CC, with the Trioval Conical Connection unique to N1 and legacy tri-channel and external hex interfaces still in the catalogue. Nothing crosses between the two brands, and within each brand the connection has to be identified.

Clinical evidence

Both brands trace their heritage in their marketing — Nobel Biocare to Brånemark's 1965 first titanium implant, Straumann to a company refocused on implantology in 1990. Heritage attaches to a company, not to every current product: the original Brånemark implant is a specific machined-surface external-hex design, and most of each brand's modern catalogue uses newer surfaces and connections. Longevity of the brand is not evidence about a particular implant.

Cost considerations

Both are premium-segment brands and priced accordingly. Patients seeking a lower price within the same corporate families are usually steered toward Neodent (Straumann Group) or Implant Direct and Alpha-Bio Tec (Envista) — legitimate products, but different ones with different connections. A low quote naming a premium brand is worth querying for exactly which product it refers to.

What may influence clinical selection

For a patient, the choice between the two brands is less important than three things a website cannot resolve: which system the surgeon is trained and stocked in, which specific implant and connection is being placed, and whether those components can be obtained where the patient lives in future. Both brands clear the availability bar across the UK and Europe; the record to keep is the system name and connection.

So which is better?

Neither is universally better, and any page telling you otherwise is selling something. These are different designs with different trade-offs, and the right choice depends on the bone available, the position in the mouth, the planned restoration, and what the treating clinician is equipped and experienced to place and to service years from now. That last point is easy to overlook and matters more than most specification differences: components need to remain obtainable for as long as the implant is in place.

Regulatory record

US FDA 510(k) clearances held by each side, retrieved from the FDA's own database.

Straumann

FDA 510(k) clearances

2004 – 2026

Filed by Institut Straumann AG

Nobel Biocare

FDA 510(k) clearances

1991 – 2026

Filed by Nobel Biocare AB

A clearance count is not a quality ranking, and the larger number is not the better implant. A brand with more clearances usually has a longer history or a broader component range. FDA "clearance" also is not FDA "approval" — it means the device was accepted as substantially equivalent to one already on the market, generally without a clinical trial. A blank here means we could not match a filing with confidence, not that the brand lacks authorisation. What these actually mean →

Sources

Numbers match the citations beside each claim above.

Primary sources

[1]Straumann Group Annual Report 2025 — Straumann Holding AG, 2026. Accessed 2026-07-21.
[2]Envista Holdings Corporation — Annual Report on Form 10-K for the year ended 31 December 2025 — U.S. Securities and Exchange Commission (EDGAR), 2026. Accessed 2026-07-21.
[3]Specialty Products & Technology — Envista — Envista Holdings Corporation. Accessed 2026-07-21.
[4]About us — Nobel Biocare — Nobel Biocare Services AG. Accessed 2026-07-21.
[5]Our story — Nobel Biocare — Nobel Biocare Services AG. Accessed 2026-07-21.
[6]Danaher Completes Acquisition Of Nobel Biocare — Danaher Corporation (distributed via PR Newswire), 2014. Accessed 2026-07-21.
[7]openFDA — Device registrations and listings — US Food and Drug Administration. Accessed 2026-07-22.